Screening for prostate cancer: an update. by Shariat, S, Scardino, P, Lilja, H

Five genetic variants associated with prostate cancer. by Vickers, A, Lilja, H, Scardino, P

Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. by Lilja, H, Vickers, A, Scardino, P

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. by Carlsson, S, Vickers, A, Roobol, M, Eastham, J, Scardino, P, Lilja, H, Hugosson, J

Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. by Stephenson, A, Kattan, M, Eastham, J, Dotan, Z, Bianco, F, Lilja, H, Scardino, P

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. by Vickers, A, Ulmert, D, Serio, A, Björk, T, Scardino, P, Eastham, J, Berglund, G, Lilja, H

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. by Steuber, T, Vickers, A, Haese, A, Kattan, M, Eastham, J, Scardino, P, Huland, H, Lilja, H

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate C... by Vickers, A, Cronin, A, Aus, G, Pihl, C, Becker, C, Pettersson, K, Scardino, P, Hugosson, J, Lilja, H

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. by Vickers, A, Cronin, A, Roobol, M, Savage, C, Peltola, M, Pettersson, K, Scardino, P, Schröder, F, Lilja, H

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. by Gupta, A, Roobol, M, Savage, C, Peltola, M, Pettersson, K, Scardino, P, Vickers, A, Schröder, F, Lilja, H

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. by Vickers, A, Cronin, A, Aus, G, Pihl, C, Becker, C, Pettersson, K, Scardino, P, Hugosson, J, Lilja, H

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. by Vickers, A, Cronin, A, Roobol, M, Savage, C, Peltola, M, Pettersson, K, Scardino, P, Schröder, F, Lilja, H

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study by Vickers, A, Cronin, A, Björk, T, Manjer, J, Nilsson, P, Dahlin, A, Bjartell, A, Scardino, P, Ulmert, D, Lilja, H

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. by Vickers, A, Cronin, A, Björk, T, Manjer, J, Nilsson, P, Dahlin, A, Bjartell, A, Scardino, P, Ulmert, D, Lilja, H

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. by Steuber, T, Vickers, A, Serio, A, Vaisanen, V, Haese, A, Pettersson, K, Eastham, J, Scardino, P, Huland, H, Lilja, H

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. by Ulmert, D, Cronin, A, Björk, T, O'Brien, M, Scardino, P, Eastham, J, Becker, C, Berglund, G, Vickers, A, Lilja, H

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. by Lilja, H, Cronin, A, Dahlin, A, Manjer, J, Nilsson, P, Eastham, J, Bjartell, A, Scardino, P, Ulmert, D, Vickers, A

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or... by Ulmert, D, Serio, A, O'Brien, M, Becker, C, Eastham, J, Scardino, P, Björk, T, Berglund, G, Vickers, A, Lilja, H

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. by Vickers, A, Gupta, A, Savage, C, Pettersson, K, Dahlin, A, Bjartell, A, Manjer, J, Scardino, P, Ulmert, D, Lilja, H

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in pati... by O'Brien, M, Cronin, A, Fearn, P, Smith, B, Stasi, J, Guillonneau, B, Scardino, P, Eastham, J, Vickers, A, Lilja, H